Researchers are exploring its potential benefits in several fields, including heart disease, cardiovascular disease, non-alcoholic fatty liver disease, and even brain-related conditions
Quick Answer: Muscle pain is not a recognized common side effect of GLP-1 receptor agonists based on FDA prescribing information and clinical trial data, though some patients report muscle discomfort likely related to rapid weight loss and muscle mass reduction rather than direct drug toxicity
When Contrave Isnt Enough And What Texas Patients Do Next Here is the part most medication guides skip entirely
Notably, our recent studies demonstrated that GDF11 promotes bone formation, whereas MSTN inhibits it, indicating that agents like follistatin, which simultaneously inhibit both GDF11 and MSTN, may increase muscle mass through MSTN inhibition but weaken bone by suppressing GDF11
Novo Nordisk has also submitted an application to the FDA for a once-daily oral formulation of semaglutide to be approved for the treatment of obesity
